NasdaqCM - Delayed Quote USD

Jupiter Neurosciences, Inc. (JUNS)

Compare
0.6280
-0.0110
(-1.72%)
At close: April 3 at 4:00:02 PM EDT
0.6499
+0.02
+(3.49%)
Pre-Market: 8:45:43 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
--
--
--
233.2810
638.0370
Operating Expense
3,091.2820
3,091.2820
3,870.7710
3,665.7280
4,545.1340
Operating Income
-3,091.2820
-3,091.2820
-3,870.7710
-3,432.4470
-3,907.0970
Net Non Operating Interest Income Expense
-242.8090
-242.8090
-218.2230
-740.2370
-113.8620
Other Income Expense
894.4660
894.4660
-694.6950
-784.8960
-179.3000
Pretax Income
-2,439.6250
-2,439.6250
-4,783.6890
-4,957.5800
-4,200.2590
Net Income Common Stockholders
-2,439.6250
-2,439.6250
-4,783.6890
-4,957.5800
-4,200.2590
Diluted NI Available to Com Stockholders
-2,439.6250
-2,439.6250
-4,783.6890
-4,957.5800
-4,200.2590
Basic EPS
-0.08
--
-0.18
-0.15
-0.44
Diluted EPS
-0.08
--
-0.18
-0.15
-0.44
Basic Average Shares
28,783.0450
--
26,405.1090
32,876.4130
9,486.6810
Diluted Average Shares
28,783.0450
--
26,405.1090
32,876.4130
9,486.6810
Total Operating Income as Reported
-3,091.2820
-3,091.2820
-3,870.7710
-3,432.4470
-3,907.0970
Total Expenses
3,091.2820
3,091.2820
3,870.7710
3,665.7280
4,545.1340
Net Income from Continuing & Discontinued Operation
-2,439.6250
-2,439.6250
-4,783.6890
-4,957.5800
-4,200.2590
Normalized Income
-3,244.0910
-3,244.0910
-4,044.4940
-4,172.6840
-4,020.9590
Interest Income
5.5570
5.5570
0.4820
0.6170
0.1320
Interest Expense
248.3660
248.3660
218.7050
740.8540
113.9940
Net Interest Income
-242.8090
-242.8090
-218.2230
-740.2370
-113.8620
EBIT
-2,191.2590
-2,191.2590
-4,564.9840
-4,216.7260
-4,086.2650
EBITDA
-2,191.2590
-2,191.2590
-4,564.9840
-4,216.7260
-4,086.2650
Net Income from Continuing Operation Net Minority Interest
-2,439.6250
-2,439.6250
-4,783.6890
-4,957.5800
-4,200.2590
Total Unusual Items Excluding Goodwill
804.4660
804.4660
-739.1950
-784.8960
-179.3000
Total Unusual Items
804.4660
804.4660
-739.1950
-784.8960
-179.3000
Normalized EBITDA
-2,995.7250
-2,995.7250
-3,825.7890
-3,431.8300
-3,906.9650
12/31/2021 - 12/3/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EXOZ eXoZymes, Inc.
10.44
+3.16%
 
PLRZ Polyrizon Ltd.
0.3590
-8.42%
 
MAZE Maze Therapeutics, Inc.
9.32
-10.13%
 
AVBP ArriVent BioPharma, Inc.
16.94
-5.89%
 
KAPA Kairos Pharma, Ltd.
0.9400
+2.34%
 
QUIA.ST Quia Pharma AB (publ)
0.0104
+79.31%
 
IMMU.ST Mendus AB (publ)
5.38
-3.24%
 
FENC Fennec Pharmaceuticals Inc.
5.59
-5.89%
 
KAN.ST Kancera AB (publ)
1.0980
-1.96%
 
ARTV Artiva Biotherapeutics, Inc.
2.5400
-11.19%